Madhu V Singh1, Michael Z Cicha2, Santosh Kumar3, David K Meyerholz4, Kaikobad Irani3, Mark W Chapleau5, François M Abboud6. 1. Department of Internal Medicine and Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, Iowa. Electronic address: madhu-singh@uiowa.edu. 2. Department of Internal Medicine and Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, Iowa; Veterans Affairs Medical Center, Iowa City, Iowa. 3. Department of Internal Medicine and Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, Iowa. 4. Department of Pathology, University of Iowa, Iowa City, Iowa. 5. Department of Internal Medicine and Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, Iowa; Veterans Affairs Medical Center, Iowa City, Iowa; Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, Iowa. 6. Department of Internal Medicine and Abboud Cardiovascular Research Center, Carver College of Medicine, University of Iowa, Iowa City, Iowa; Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, Iowa. Electronic address: francois-abboud@uiowa.edu.
Abstract
BACKGROUND: Hypertension is considered an immunologic disorder. However, the role of the IL-17 family in genetic hypertension in the spontaneously hypertensive rat (SHR) has not been investigated. OBJECTIVE: We tested the hypothesis that enhanced TH17 programming and IL-17 expression in abundant CD161+ immune cells in SHRs represent an abnormal proinflammatory adaptive immune response. Furthermore, we propose that this response is driven by the master regulator retinoic acid receptor-related orphan receptor γt (RORγt) and a nicotinic proinflammatory innate immune response. METHODS: We measured expression of the CD161 surface marker on splenocytes in SHRs and normotensive control Wistar-Kyoto (WKY) rats from birth to adulthood. We compared expression of IL-17A and IL-17F in splenic cells under different conditions. We then determined the functional effect of these cytokines on vascular reactivity. Finally, we tested whether pharmacologic inhibition of RORγt can attenuate hypertension in SHRs. RESULTS: SHRs exhibited an abnormally large population of CD161+ cells at birth that increased with age, reaching more than 30% of the splenocyte population at 38 weeks. The SHR splenocytes constitutively expressed more RORγt than those of WKY rats and produced more IL-17F on induction. Exposure of WKY rat aortas to IL-17F impaired endothelium-dependent vascular relaxation, whereas IL-17A did not. Moreover, in vivo inhibition of RORγt by digoxin decreased systolic blood pressure in SHRs. CONCLUSIONS: SHRs have a markedly enhanced potential for RORγt-driven expression of proinflammatory and prohypertensive IL-17F in response to innate immune activation. Increased RORγt and IL-17F levels contribute to SHR hypertension and might be therapeutic targets.
BACKGROUND:Hypertension is considered an immunologic disorder. However, the role of the IL-17 family in genetic hypertension in the spontaneously hypertensiverat (SHR) has not been investigated. OBJECTIVE: We tested the hypothesis that enhanced TH17 programming and IL-17 expression in abundant CD161+ immune cells in SHRs represent an abnormal proinflammatory adaptive immune response. Furthermore, we propose that this response is driven by the master regulator retinoic acid receptor-related orphan receptor γt (RORγt) and a nicotinic proinflammatory innate immune response. METHODS: We measured expression of the CD161 surface marker on splenocytes in SHRs and normotensive control Wistar-Kyoto (WKY) rats from birth to adulthood. We compared expression of IL-17A and IL-17F in splenic cells under different conditions. We then determined the functional effect of these cytokines on vascular reactivity. Finally, we tested whether pharmacologic inhibition of RORγt can attenuate hypertension in SHRs. RESULTS: SHRs exhibited an abnormally large population of CD161+ cells at birth that increased with age, reaching more than 30% of the splenocyte population at 38 weeks. The SHR splenocytes constitutively expressed more RORγt than those of WKY rats and produced more IL-17F on induction. Exposure of WKY rat aortas to IL-17F impaired endothelium-dependent vascular relaxation, whereas IL-17A did not. Moreover, in vivo inhibition of RORγt by digoxin decreased systolic blood pressure in SHRs. CONCLUSIONS: SHRs have a markedly enhanced potential for RORγt-driven expression of proinflammatory and prohypertensive IL-17F in response to innate immune activation. Increased RORγt and IL-17F levels contribute to SHR hypertension and might be therapeutic targets.
Authors: Dean Toy; David Kugler; Martin Wolfson; Tim Vanden Bos; Jesse Gurgel; Jonathan Derry; Joel Tocker; Jacques Peschon Journal: J Immunol Date: 2006-07-01 Impact factor: 5.422
Authors: M Iantorno; U Campia; N Di Daniele; S Nistico; G B Forleo; C Cardillo; M Tesauro Journal: J Biol Regul Homeost Agents Date: 2014 Apr-Jun Impact factor: 1.711
Authors: María N Lardizábal; Ana L Nocito; Stella M Daniele; Leonardo A Ornella; Javier F Palatnik; Luis M Veggi Journal: PLoS One Date: 2012-05-01 Impact factor: 3.240
Authors: Adriana Osickova; Nataliya Balashova; Jiri Masin; Miroslav Sulc; Jana Roderova; Tomas Wald; Angela C Brown; Evan Koufos; En Hyung Chang; Alexander Giannakakis; Edward T Lally; Radim Osicka Journal: Emerg Microbes Infect Date: 2018-11-07 Impact factor: 7.163
Authors: Shobana Navaneethabalakrishnan; Hannah L Smith; Cristina M Arenaz; Bethany L Goodlett; Justin G McDermott; Brett M Mitchell Journal: Am J Hypertens Date: 2022-10-03 Impact factor: 3.080